<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1812-9528</journal-id>
<journal-title><![CDATA[Memorias del Instituto de Investigaciones en Ciencias de la Salud]]></journal-title>
<abbrev-journal-title><![CDATA[Mem. Inst. Investig. Cienc. Salud]]></abbrev-journal-title>
<issn>1812-9528</issn>
<publisher>
<publisher-name><![CDATA[Instituto de Investigaciones en Ciencias de la Salud]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1812-95282021000300006</article-id>
<article-id pub-id-type="doi">10.18004/mem.iics/1812-9528/2021.019.03.06</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Comparación de los perfiles de disolución de los comprimidos de Losartán potásico 100mg nacionales e importados vs precio, Paraguay (2019)]]></article-title>
<article-title xml:lang="en"><![CDATA[Comparison of dissolution profiles vs price of national and imported 100 mg potassic losartan tablets, Paraguay (2019)]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fretes de Aquino]]></surname>
<given-names><![CDATA[Sonia Lorena]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lugo]]></surname>
<given-names><![CDATA[Gladys]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Samaniego]]></surname>
<given-names><![CDATA[Lourdes]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[de Larroza]]></surname>
<given-names><![CDATA[Mabel Maidana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Nacional de Asunción Facultad de Ciencias Químicas ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Paraguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<volume>19</volume>
<numero>3</numero>
<fpage>6</fpage>
<lpage>11</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_arttext&amp;pid=S1812-95282021000300006&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_abstract&amp;pid=S1812-95282021000300006&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.iics.una.py/scielo.php?script=sci_pdf&amp;pid=S1812-95282021000300006&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN La hipertensión arterial es el principal factor de riesgo cardiovascular, y su prevalencia en Paraguay es la mayor de América Latina. El objetivo del presente trabajo fue comparar productos de losartán de 100 mg comprimidos de producción nacional e importada a través de los perfiles de disolución versus su precio. Se tomaron 8 marcas de losartán potásico comercializadas durante el 2017, realizándose los controles de calidad de acuerdo a lo establecido en la Farmacopea Americana (USP 38). Se determinó el porcentaje de principio activo liberado en el medio de disolución establecido por la USP 38, por medio de los perfiles de disolución. Las determinaciones se realizaron por HPLC y espectrofotometría UV/V. Los controles realizados cumplieron con las especificaciones establecidas por la USP 38. No se encontraron diferencias significativas en el análisis estadístico de los perfiles de disolución de las diferentes marcas analizadas. Los resultados demostraron que los precios de las marcas analizadas no afectaban la calidad de los productos, pero sí en el costo del tratamiento de la población de escasos recursos, debido al mayor costo de los productos importados con respecto a los de producción nacional.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT Hypertension is the main cardiovascular risk factor, and its prevalence in Paraguay is the highest in Latin America. The objective of the present work was to compare products of 100 mg losartan tablets made in Paraguay and imported products, through dissolution profiles versus price. Eight brands of potassic losartan commercialized during 2017 were subjected to quality controls in accordance with the provisions of the American Pharmacopoeia (USP 38). The percentage of active principle released in the dissolution medium established by USP 38 was determined by means of dissolution profiles. The determinations were made by HPLC and UV/V spectrophotometry. The controls carried out complied with the specifications established by USP 38. No significant differences were found in the statistical analysis of the dissolution profiles of the different brands analyzed. The results showed that the prices of the brands analyzed did not affect the quality of the products, but they affected the cost of treatment of the low-income population due to the higher cost of imported products compared to those of national production.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Losartán potásico]]></kwd>
<kwd lng="es"><![CDATA[hipertensión arterial]]></kwd>
<kwd lng="es"><![CDATA[perfiles de disolución]]></kwd>
<kwd lng="en"><![CDATA[Losartan potassium]]></kwd>
<kwd lng="en"><![CDATA[arterial hypertension]]></kwd>
<kwd lng="en"><![CDATA[dissolution profiles]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hergueta]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[Guía de Hipertensión Arterial]]></source>
<year>2002</year>
<edition>2</edition>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Norma-Capitel Editores]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<collab>Ministerio de Salud Pública y Bienestar Social</collab>
<source><![CDATA[Cinco de cada diez paraguayos padece hipertensión]]></source>
<year>2014</year>
<publisher-name><![CDATA[MSPyBS]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<collab>Comisión Provincial de Medicamentos</collab>
<source><![CDATA[Protocolo de uso para Losartán]]></source>
<year>2015</year>
<page-range>1-11</page-range><publisher-loc><![CDATA[Provincia de Santa Fe ]]></publisher-loc>
<publisher-name><![CDATA[Ministerio de Salud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="">
<source><![CDATA[Análisis del Sector Farmacéutico Nacional FINAL.pdf]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Matiz Melo]]></surname>
<given-names><![CDATA[GE]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez Cavallo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estudio comparativo de la calidad biofarmacéutica de marcas comerciales y multifuentes de tabletas de captopril y losartán del mercado colombiano]]></article-title>
<source><![CDATA[Rev. Colomb. Cienc. Quim. Farm.]]></source>
<year>2014</year>
<volume>43</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>217-33</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fretes]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Vázquez Mesa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lugo Rodríguez]]></surname>
<given-names><![CDATA[GB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation comparative between dissolution profiles of tablets 25mg Lamotrigine similar and innovative drug, traded in Paraguay]]></article-title>
<source><![CDATA[Mem Inst Investig en Cienc Salud]]></source>
<year>2016</year>
<volume>14</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>53-60</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Saavedra S]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Iturriaga V]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Ávila M]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Quiñones S]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estudios de bioexención (in vitro) para establecer equivalencia de medicamentos (Spanish)]]></article-title>
<source><![CDATA[Cuadernos Médico Sociales]]></source>
<year>2011</year>
<volume>51</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>66-79</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<collab>United States Pharmacopeial Convention</collab>
<source><![CDATA[Farmacopea de los Estados Unidos]]></source>
<year>2015</year>
<publisher-loc><![CDATA[Rockville (EEUU) ]]></publisher-loc>
<publisher-name><![CDATA[U.S. Pharmacopeial Convention]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lindenberg]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Kopp]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Dressman]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Classification of orally administered drugs on the World Health Organization model list of essential medicines according to the Biopharmaceutics Classification System Eur. J. Pharm]]></article-title>
<source><![CDATA[Biopharm,]]></source>
<year>2004</year>
<volume>58</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>265-78</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Takagi]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ramachandran]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bermejo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Yamashitas]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[LX]]></given-names>
</name>
<name>
<surname><![CDATA[Amidon]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A provisional Biopharmaceutical classification of the top 200 oral drug products in the Unites states, Great Britain, Spain and Japan. Mol]]></article-title>
<source><![CDATA[Pharm,]]></source>
<year>2006</year>
<volume>3</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>631-43</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Amido]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
<name>
<surname><![CDATA[Lennernäs]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[VP]]></given-names>
</name>
<name>
<surname><![CDATA[Crison]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A theoretical basis for a biopharmaceutic drug classification The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm]]></article-title>
<source><![CDATA[Res,]]></source>
<year>1995</year>
<volume>12</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>413-20</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="book">
<collab>OMS</collab>
<source><![CDATA[Información general sobre la hipertensión 1 en el mundo]]></source>
<year>2013</year>
<publisher-loc><![CDATA[Ginebra(Suiza) ]]></publisher-loc>
<publisher-name><![CDATA[Organización Mundial de la Salud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="">
<collab>FDA, Guidance for Industry</collab>
<source><![CDATA[Dissolution testing of immediate-release solid oral dosage forms, Food and Drug Administration, Center for Drug Evaluation and Research (CDER)]]></source>
<year>1997</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
